These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 202966)

  • 1. Reduction of serum cholesterol in type II hyperlipidaemia by guar gum.
    Jenkins DJ; Leeds AR; Slavin B; Mann J; Jepson EM
    Proc Nutr Soc; 1977 Dec; 36(3):94A. PubMed ID: 202966
    [No Abstract]   [Full Text] [Related]  

  • 2. Dietary fiber and blood lipids: reduction of serum cholesterol in type II hyperlipidemia by guar gum.
    Jenkins DJ; Leeds AR; Slavin B; Mann J; Jepson EM
    Am J Clin Nutr; 1979 Jan; 32(1):16-8. PubMed ID: 216259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind evaluation of guar gum in patients with dyslipidaemia.
    Tuomilehto J; Karttunen P; Vinni S; Kostiainen E; Uusitupa M
    Hum Nutr Clin Nutr; 1983 Mar; 37(2):109-16. PubMed ID: 6345478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 5. Guar gum in hyperlipidaemia.
    Jenkins DJ; Leeds AR; Slavin B; Jepson EM
    Lancet; 1976 Dec; 2(7999):1251. PubMed ID: 63798
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnosis and treatment of Type II and Type IV hyperlipoproteinemia in the office practice setting.
    Millett F; Sielski J; Stoll H; Alston N; Gail S
    PA J; 1976; 6(2):54-9. PubMed ID: 10235781
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of hyperlipoproteinemias (author's transl)].
    Crepaldi G; Fellin R; Briani G; Baggio G; Baiocchi MR
    G Ital Cardiol; 1974; 4(3):332-40. PubMed ID: 4367439
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evaluation of cinnarizine in hyperlipaemic patients.
    Saba P; Galeone F; Salvadorini F; Guarguaglini M; Houben JL
    G Clin Med; 1974 Aug; 55(8):586-99. PubMed ID: 4377134
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study on the selective removal of plasma low-density lipoprotein and fibrinogen by degraded guar sulfate].
    Zhu Y; Fang B; Huang L; Guan C; Yang G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Oct; 25(5):1135-40. PubMed ID: 19024462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dyslipoproteinemias.
    Brown DF
    Acta Diabetol Lat; 1972 Dec; 9 Suppl 2():18-52. PubMed ID: 4369284
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of highly purified D-thyroxine ("Dyno") in hyperlipoproteinemias type II a and II b].
    von Löwis of Menar P; Klemens UH
    Verh Dtsch Ges Inn Med; 1972; 78():1623-5. PubMed ID: 4353152
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
    Napoli C; Lepore S; Ambrosio G; Chiariello M
    Cardiologia; 1992 Nov; 37(11):761-8. PubMed ID: 1298545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperlipidemia.
    Sloan RW
    Am Fam Physician; 1983 Sep; 28(3):171-82. PubMed ID: 6613796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of hyperlipoproteinemias type II a and II b using dextro-thyroxine or D,L-alpha-methyl-thyroxine-ethylester].
    Schwartzkopff W
    Verh Dtsch Ges Inn Med; 1972; 78():1621-3. PubMed ID: 4353151
    [No Abstract]   [Full Text] [Related]  

  • 16. Long term effects of guar gum on metabolic control, serum cholesterol and blood pressure levels in type 2 (non-insulin-dependent) diabetic patients with high blood pressure.
    Uusitupa M; Tuomilehto J; Karttunen P; Wolf E
    Ann Clin Res; 1984; 16 Suppl 43():126-31. PubMed ID: 6398982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients.
    Yoshida H; Hirowatari Y; Kurosawa H; Tada N
    Clin Sci (Lond); 2005 Sep; 109(3):297-302. PubMed ID: 15907189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
    Venkatesan N; Devaraj SN; Devaraj H
    Eur J Nutr; 2003 Oct; 42(5):262-71. PubMed ID: 14569407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.